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brane proteins (Lax et al., 1989). It is now well estab-
lished that growth factor-induced receptor oligomeriza-
tion is responsible for the activation of receptor tyrosine
kinases and other receptors that contain a single trans-
membrane domain (reviewed in Jiang and Hunter, 1999).
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Growth factor-induced receptor dimerization is followed
by intermolecular autophosphorylation of key tyrosineThe EGF receptor mediates many cellular responses
residues in the activation loop of the catalytic PTK do-in normal biological processes and in pathological
main resulting in stimulation of PTK activity. Tyrosinestates. Recent structural studies reveal the molecular
autophosphorylation sites in other parts of the cyto-basis for ligand binding specificity and how ligand
plasmic domain serve as docking sites for SH2 and PTBbinding induces receptor dimerization. Receptor di-
domains of signaling proteins that are recruited andmerization is mediated by receptor-receptor interac-
activated upon growth factor stimulation (Pawson andtions in which a loop protruding from neighboring re-
Schlessinger, 1993).ceptors mediates receptor dimerization and activation.
While biophysical studies have shown that two EGF
molecules bind to two receptor molecules within theReceptor and cytoplasmic protein tyrosine kinases play
context of EGFR dimers (Lemmon et al., 1997), thea prominent role in the control of a variety of cellular
mechanism of EGF-induced EGFR dimerization was notprocesses during embryonic development and in the
understood. Now, two structures of ligand:receptorregulation of many metabolic and physiological pro-
complexes are described in this issue of Cell. Garrettcesses in a variety of tissues and organs (Hunter, 2000;
et al. (2002) describe the X-ray crystal structure of aSchlessinger, 2000; Pawson et al., 2001). Consequently,
deletion mutant of the extracellular domain of EGFRdysfunctions in the action of protein tyrosine kinases or
lacking almost the entire domain IV in complex withaberrations in the activities and cellular localization of
TGF at 2.5 A˚ resolution. Ogiso et al. (2002) crystallizedkey components of the signaling pathways they activate
the entire extracellular domain of EGFR in complex withwill result in severe diseases such as cancer, diabetes,
EGF and determined the structure at a resolution ofimmune deficiencies, and cardiovascular diseases,
3.3 A˚. Since most of domain IV is disordered, this struc-among many others (Blume-Jensen and Hunter, 2001).
ture contains the same region as seen in the deletionThe epidermal growth factor receptor (EGFR) was the
mutant lacking most of domain IV. Both structures pro-first receptor tyrosine kinase (RTK) to be discovered
vide a very similar view of a 2:2 receptor:ligand complex.(Carpenter et al., 1978). Moreover, most of the principles
Specifically, both structures demonstrate that TGF orand paradigms that underlie the action of receptor tyro-
EGF make similar sets of contacts with a single EGFRsine kinases were first established for the EGFR (Schles-
molecule through specific regions in both domain I andsinger, 2000). Similarly, many of the mechanisms for
domain III of the extracellular domain. The structureactivation and recruitment of intracellular signaling path-
shows that the B loop of EGF interacts with domain Iways following growth factor stimulation were discov-
while residues from the A loop and from the C-terminalered in studies of signaling via EGF receptors (Pawson
region of EGF interact with domain III of EGFR. Further-and Schlessinger, 1993). Following the identification of
more, the assignment of the EGF and TGF binding
EGFR, three additional members of the same receptor
domains in the two structures is consistent with previous
family were identified, ErbB2, ErbB3, and ErbB4. These
mutagenesis and chemical crosslinking results. More
receptors can be activated by EGF, TGF, and ten addi- than one dimeric arrangement of 1:1 ligand:receptor
tional potential ligands. Activating mutations and over- complex is observed in each structure due to crystal
expression of members of this family of receptors were symmetry. In one dimer arrangement, domain I of one
implicated in a variety of cancers, including mammary EGFR interacts with domain III of a second EGFR with
carcinomas, squamous carcinomas, and glioblastomas, a relative small buried surface area. The second dimer
as well as other malignant diseases (Blume-Jensen and arrangement, termed the “back-to-back” dimer, is seen
Hunter, 2001). in both structures and is most likely to be physiologically
Like all RTKs, the EGFR family is composed of an relevant.
extracellular ligand binding domain, followed by a single In this arrangement, the extracellular domain of EGFR
transmembrane domain and a cytoplasmic domain con- dimerizes by virtue of homophilic interactions involving
taining a conserved protein tyrosine kinase (PTK) core, a specific loop projecting from each of the domain II
flanked by regulatory sequences. The extracellular do- cysteine-rich regions of the two adjoining extracellular
mains of the EGFR family members are composed of domains (“dimerization loop”; Figure 1A). Indeed, point
four subdomains designated domain I, II, III, and IV or mutations in key residues or deletion of the dimerization
L1, S1, L2, and S2, respectively. It was proposed that loop prevents EGF-induced signaling via EGFR (Ogiso
domains I and III form the ligand binding domain of EGFR et al., 2002; Garrett et al., 2002)
while other parts of the extracellular domain mediate Dimerization of EGFR requires the binding of two mol-
receptor dimerization and interactions with other mem- ecules of monomeric EGF to two EGFR molecules in a
2:2 EGF:EGFR complex formed from stable intermedi-
ates of 1:1 EGF:EGFR complexes (Lemmon et al., 1997).1Correspondence: joseph.schlessinger@yale.edu
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stants: a minority (2%–5%) of high-affinity (0.1 nM) re-
ceptors and a majority (95%–98%) of low-affinity (10
nM) receptors. The high-affinity receptors are lost upon
membrane solubilization or following protein kinase
C-mediated phosphorylation of Thr-654 in the juxta-
membrane domain of EGFR (reviewed in Ullrich and
Schlessinger, 1990). In addition, a soluble form of the
extracellular domain exhibits low-affinity binding toward
EGF, while a truncated form lacking most of the second
cysteine-rich domain (IV) binds EGF or TGF with at
least ten-fold higher affinity than the full-length ECD
(Garrett et al., 2002). It was also reported that the binding
affinity of EGF toward EGFR is modulated by coexpres-
sion of ErbB2, or ErbB3 in the same cells, two members
of the receptor family that do not bind directly to EGF.
Similar modulation of the binding affinity of Heregulin
toward ErbB3 or ErbB4 was also detected in cells coex-
pressing EGFR or ErbB2. The crystal structures pre-
sented in the two reports provide new insights into these
puzzling observations.
Figure 1. Model for Receptor-Mediated Mechanism of EGF Recep-
By comparing the previously described structure oftor Dimerization
the extracellular domain of the IGF1 receptor (Garrett
(A) The crystal structures describe the ligand binding domain of
et al., 1998) to the structure of the ligand-occupiedEGF receptor in complex with EGF or TGF. Receptor dimerization
EGFR, both groups propose that the conformation ofis mediated by a protrusion in domain II (dimerization loop, red
the dimerization loop is coupled to the binding of EGFcolor) that interacts with a specific region in the adjoining receptor
to bring about receptor-receptor interactions. It is assumed that the to the ligand binding cleft between domains I and III
dimerization loop in the unoccupied receptor adopts a conformation (Ogiso et al., 2002; Garrett et al., 2002). Moreover, com-
(colored blue) that does not facilitate receptor-receptor interactions. parison of the bound and unbound receptor structures
In addition, intramolecular domain II-IV interactions may also main-
suggests that the relative conformation and angle be-tain the EGF receptor in an inactive state.
tween domains I and III is altered as a consequence of(B) Alignment of the amino acid sequence of the dimerization loop
ligand binding. This raises the possibility that the relativeof EGF receptor (marked by arrows) with the corresponding se-
quences in ErbB2, ErbB3, and ErbB4. The residues in red and blue orientation of domains I and III is allosterically linked to
mark amino acids that are identical in three or two members of the a change in conformation of the dimerization loop that
EGF receptor family, respectively. enables receptor dimerization. Moreover, changes in the
conformation of the dimerization loop may influence the
Two models were previously proposed for how EGF or relative positions of domains I and III to control EGF
Heregulin induce receptor dimerization. In one model, binding affinity. Indeed, Garrett et al. (2002) demonstrate
EGFR dimerization is mediated by the bivalency of EGF that deletion of the dimerization loop reduces ligand
toward EGFR (Gullick, 1994), resulting in EGFR dimeriza- binding affinity and ligand-induced tyrosine autophos-
tion (“ligand-mediated” mechanism). This model is simi- phorylation of the mutated EGFR. Bidirectional control,
lar to the mechanism of growth hormone (GH)-induced including “inside-out” regulation of EGF binding affinity
dimerization of growth hormone receptor (GHR) in which toward EGFR that is induced by heterodimerization with
a monomeric GH binds to two GHR molecules to form other ErbB family members that do not bind EGF, could
a 1:2 GH:GHR complex (de Vos et al., 1992). It was be mediated by their effects on the conformation of
proposed that dimerization of EGFR and hetero- domain II and interactions mediated by the dimerization
dimerization of erbB3 and erbB4 with other members loop. In addition, because of the internal flexibility of the
of the EGFR family are mediated by the bivalency of unoccupied extracellular domain of EGFR suggested
EGF (Gullick, 1994) or Heregulin (Tzahar et al., 1997) by these structures, different populations of unbound
toward EGFR and other members of the family. The EGFR may exist on the cell surface, exhibiting different
crystal structures of EGFR in complex with EGF or TGF orientations of domain I relative to domain III, possibly
described in the two papers appear to rule out this accounting for the heterogeneity in the dissociation con-
stants of EGF toward EGFR. The recent structure of themechanism. In both structures, each ligand (EGF or
TGF) molecule is bound exclusively to a single EGFR extracellular domain of ErbB3 (Cho and Leahy, 2002)
suggests that deletion of domain IV will release an au-molecule, and dimerization is mediated entirely by re-
ceptor-receptor interactions. The crystal structures are toinhibition conferred upon ligand binding by contacts
between domains IV and II that constrain the relativeinstead consistent with the “receptor-mediated” mecha-
nism for dimerization (Lemmon et al., 1997), in which orientation of domains I and III, resulting in reduced
ligand binding affinity (Figure 2A).the binding of EGF to EGFR induces a conformational
change that exposes a receptor-receptor interaction site Homo- and Heterodimerization of EGFR
by a Receptor-Mediated Mechanismin the extracellular domain, resulting in dimerization of
two EGFR monomers only when occupied by EGF. EGFR is also known to undergo heterodimerization with
ErbB2, ErbB3, or ErbB4 in response to EGF stimulation,Regulation of Ligand Binding Affinity
Quantitative binding experiments demonstrated that resulting in their tyrosine phosphorylation (Graus-Porta
et al., 1997). While ErbB3 and ErbB4 function as surfaceEGF binds to EGFR with two distinct dissociation con-
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high concentration of ErbB2 even in the absence of
ligand binding, resulting in stimulation of PTK activity
and cell transformation.
What Is the Function of the Second
Cysteine-Rich Domain?
The extracellular domain of all members of the EGFR
family contains two homologous cysteine-rich domains
designated domains II and IV or S1 and S2, respectively
(Abe et al., 1998). The structures of the extracellular
domain of EGFR described in the two papers do not
provide any information about the second cysteine do-
main, since in one study most of this domain was deleted
(Garrett et al., 2002) and in the second structure, domain
IV was disordered (Ogiso et al., 2002). The recently de-
scribed crystal structure of the extracellular domain of
ErbB3 (Cho and Leahy, 2002) has shown that domain
IV regulates ligand binding affinity by intramolecular in-
teractions. Autoinhibition is mediated by interactions
between domain IV and domain II that constrain the
Figure 2. Autoinhibition of EGFR by Intramolecular Interactions relative orientation of domains I and III, resulting in re-
(A) A model for autoinhibition of EGFR based on the structure of duced ligand binding affinity (Figure 2A). The structure
ErbB3 (Cho and Leahy, 2002). Autoinhibition is mediated by domain of EGFR shows that the first cysteine-rich domain is
II-IV contacts that constrain the relative orientation between do- responsible for at least two functions; it acts as a scaf-
mains I and III, resulting in reduced EGF binding affinity. fold that positions domains I and III in an orientation
(B) Alignment of the amino acid sequence of a region in domain IV
that generates a binding pocket for EGF and TGF inthat is responsible for mediating domain II-IV interactions in ErbB3
the cleft formed between the two juxtaposed domains.and may play a similar role in other members of the EGFR family.
In addition, the second cysteine-rich domain (domainThis region may also participate in mediating additional receptor-
receptor interactions. The residues in red and blue mark amino acids IV) may interact with domain II via a conserved region
that are identical in three or two members of the EGFR family, that includes a cysteine-rich loop (amino acids 560–590)
respectively. similar to the autoinhibitory intramolecular interactions
revealed by the structure of the extracellular domain of
ErbB3 (Figure 2B; Cho and Leahy, 2002). Following li-receptors for Heregulin, the physiological ligand of
gand binding and the release of the autoinhibition con-ErbB2 is still unknown. It is possible that ErbB2 may not
ferred by domain II-IV interactions, domain IV may func-have a ligand and that this receptor mediates its cellular
tion as a spacer that controls the orientation of theresponses by functioning as a partner for heterodi-
extracellular domain relative to the transmembrane do-
merization with EGFR, ErbB3, or ErbB4 (Graus-Porta et
main and the plasma membrane. In addition, the putative
al., 1997). The receptor-mediated mechanism of EGFR
dimerization loop in domain IV may function as an addi-
dimerization provides a simple paradigm for homo- and
tional site of receptor-receptor interaction to stabilize
heterodimerization of the EGFR family of receptors. In- the dimers formed by the dimerization loop of domain
spection of the primary structure of the dimerization II and to mediate the formation of higher oligomerization
loop shows that this loop is highly conserved among all states such as receptor tetramers.
members of the EGFR family (Figure 1B). It is plausible Mechanism of Activation of EGFR
that the corresponding dimerization loops of ErbB3 or It is generally accepted that ligand-induced activation of
ErbB4 mediate Heregulin-induced homodimerization of receptor tyrosine kinases is mediated by intermolecular
the receptors. Moreover, the conservation of key resi- autophosphorylation of key tyrosine(s) residues in the
dues of the dimerization loops of the different ErbB activation loop of the catalytic PTK domain. In the inac-
receptors suggests that this interaction may be suffi- tive PTK, the activation loop adopts a configuration pre-
ciently promiscuous to enable the formation of hetero- venting access to ATP and substrate. Upon tyrosine
dimers between different members of the ErbB family phosphorylation, the activation loop adopts an “open
of receptors. It was proposed that ErbB2 is a preferred configuration” enabling access to ATP and substrate,
partner for heterodimerization with all members of the thus resulting in enhanced PTK activity. Indeed, muta-
EGFR family (Graus-Porta et al., 1997). A potential expla- tions that render the activation loop in an open configu-
nation for this phenomenon is that ErbB2 has evolved ration result in enhanced PTK activity, while mutation
to act as an RTK without a ligand, with its dimerization of key tyrosine residues in the activation loop prevents
loop maintained constitutively in the open, active config- PTK activation. By contrast to virtually all PTKs, muta-
uration. This could allow homodimerization of ErbB2 in tion in a conserved tyrosine residue in the activation
the absence of ligand and its heteroligomerization with loop of EGFR is dispensable for protein tyrosine kinase
other members of the EGFR family following ligand- activation and for signaling via the EGFR (Gotoh et al.,
induced conformational change in their dimerization 1992). This may indicate that the activation loop of EGFR
loops. Such a mechanism may account for the high does not play a prominent role in autoinhibition of the
activity of ErbB2 in human cancer cells that overexpress PTK domain of EGFR as shown for other protein tyrosine
the ErbB2 protein. Because of the active configuration kinases. In other words, the inactive EGFR is not as
tightly autoinhibited as the inactive forms of other PTKs.of its activation loop, dimerization may be driven by the
Cell
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Indeed, ErbB2 exhibits a PTK activity even in the ab-
sence of ligand stimulation. Moreover, the PTK activity
is strongly enhanced upon overexpression of ErbB2 re-
sulting in cell transformation.
The dimerization loop-mediated mechanism of recep-
tor dimerization may function as a key regulatory step
for control of the PTK activity of EGFR and other mem-
bers of the family. Accordingly, EGF-induced receptor-
mediated dimerization will facilitate intermolecular auto-
phosphorylation that in turn will maintain the PTK do-
main in an active state. Receptor-mediated dimerization
may also provide a potential explanation for the strong
stimulation of the PTK activity caused by overexpres-
sion of erbB2. As the dimerization loop of ErbB2 is main-
tained in the active configuration, overexpression of
ErbB2 will facilitate spontaneous dimerization of the re-
ceptor, resulting in trans autophosphorylation and fur-
ther stimulation of ErbB2 PTK activity.
Future structural and biochemical experiments will
reveal the potential role of the second cysteine-rich do-
main (domain IV) in receptor autoinhibition and control of
receptor oligomerization and the important unanswered
question of how ligand-induced receptor dimerization
activates the cytoplasmic protein tyrosine kinase ac-
tivity.
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